The government-funded insurance plan will now pay for the drug for patients with obstructive sleep apnea, a condition that afflicts many severely obese people.

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the ...

Medicare won't seek to negotiate lower prices for Eli Lilly's popular diabetes drug Mounjaro and weight loss drug Zepbound because they haven't been on the market long enough to be eligible.

The 15 drugs selected for negotiation are prescribed to 5.3 million Medicare beneficiaries to treat conditions ranging from ...

Neither Medicare nor Medicaid covers weight loss medications like Zepbound. While Eli Lilly doesn’t offer specific pricing information for Zepbound, it has a savings program. With eligible ...

Novo Nordisk stock falls as Medicare selects its marketed semaglutide medicines catering to T2D and obesity for price ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...